Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated ...
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed. According to research presented at the European ...
Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer. Patients with previously treated, inoperable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback